They found that oxaliplatin-cyclophosphamide (OXA-CYC) treatment could significantly enhance HMGB1 staining in KP tumors (KRAS and Trp53 mutations) and directly activate the upregulation of toll-like receptor 4 (TLR4) expression in dendritic cells and macrophages, further increasing the ratio of CD8+ T cells to Tregs. The gene discussed is TLR4; the disease is keratosis pilaris.